LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

Search

MannKind Corp

Fechado

SetorSaúde

4.52 11.33

Visão Geral

Variação de preço das ações

24h

Atual

Mín

4.06

Máximo

4.61

Indicadores-chave

By Trading Economics

Rendimento

-12M

668K

Vendas

-1.8M

77M

P/E

Médio do Setor

35.455

35.724

Margem de lucro

0.873

Funcionários

403

EBITDA

-17M

9.7M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+108.63% upside

Dividendos

By Dow Jones

Próximos Ganhos

6 de nov. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

5.2M

1.2B

Abertura anterior

-6.81

Fecho anterior

4.52

Sentimento de Notícias

By Acuity

72%

28%

351 / 372 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Bullish Evidence

MannKind Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

27 de ago. de 2025, 22:51 UTC

Ganhos

Wesfarmers Plans Special Payout to Shareholders as Annual Net Profit Rises 14%

27 de ago. de 2025, 23:57 UTC

Ganhos

Trip.com Group 1H Rev $4.01B

27 de ago. de 2025, 23:57 UTC

Ganhos

Trip.com Group 1H Adj EPS $1.84

27 de ago. de 2025, 23:57 UTC

Ganhos

Trip.com Group 1H EPS $1.82

27 de ago. de 2025, 23:50 UTC

Conversa de Mercado

Nikkei May Decline Amid Caution Over Tariff Impact, Chip Demand -- Market Talk

27 de ago. de 2025, 23:39 UTC

Ganhos

Correction to Nvidia Earnings Article -- WSJ

27 de ago. de 2025, 22:59 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

27 de ago. de 2025, 22:59 UTC

Conversa de Mercado

HP CEO Sees Strong Back-to-School Spending on PCs -- Market Talk

27 de ago. de 2025, 22:58 UTC

Ganhos

South32 Records Significant Items of $71 Million Tied to Worsley, Mozal

27 de ago. de 2025, 22:57 UTC

Ganhos

South32 FY Free Cash Flow $192 Million

27 de ago. de 2025, 22:56 UTC

Ganhos

South32 FY Total Capital Expenditure $1.35 Billion

27 de ago. de 2025, 22:56 UTC

Ganhos

South32 FY Capital Expenditure $963 Million, Excluding EAIs

27 de ago. de 2025, 22:55 UTC

Ganhos

South32 Net Cash $123 Million at June 30

27 de ago. de 2025, 22:54 UTC

Ganhos

South32: Focused on Maintaining Strong Operating Momentum

27 de ago. de 2025, 22:53 UTC

Ganhos

South32: $144 Million Remains to be Returned to Shareholders Under Program

27 de ago. de 2025, 22:53 UTC

Ganhos

South32 Extends Capital Management Program for 12 Months

27 de ago. de 2025, 22:52 UTC

Ganhos

South32 FY Underlying Ebitda $1.93 Billion, Up 7% On-Year

27 de ago. de 2025, 22:51 UTC

Ganhos

South32 FY Revenue $5.78 Billion, Up 17% On-Year

27 de ago. de 2025, 22:51 UTC

Ganhos

South32 FY Underlying Earnings $666 Million, Up 75% On-Year

27 de ago. de 2025, 22:50 UTC

Ganhos

South32 to Pay Final Dividend of 2.6 U.S. Cents/Share

27 de ago. de 2025, 22:50 UTC

Ganhos

South32 FY Net Profit $213 Million Vs $203 Million Loss Year Earlier

27 de ago. de 2025, 22:45 UTC

Ganhos

Sandfire Resources Expects FY26 Matsa Capital Expenditure of $148 Million

27 de ago. de 2025, 22:44 UTC

Ganhos

Sandfire Resources Expects FY26 Motheo Unit Cost of $44/Ton of Ore Processed

27 de ago. de 2025, 22:44 UTC

Ganhos

Sandfire Resources Expects FY26 Motheo Capital Expenditure of $82 Million

27 de ago. de 2025, 22:43 UTC

Ganhos

Sandfire Resources Expects FY26 Matsa Unit Cost of $86/Ton of Ore Processed

27 de ago. de 2025, 22:43 UTC

Ganhos

Nvidia Breaks Sales Record Despite Chinese Trade Hiccups -- 5th Update

27 de ago. de 2025, 22:42 UTC

Ganhos

Sandfire Resources Expects FY26 Motheo Copper Eq Output to Rise 3% to 61,000 Tons

27 de ago. de 2025, 22:42 UTC

Ganhos

Sandfire Resources Expects FY26 Matsa Copper Eq Output to Rise 2% to 96,000 Tons

27 de ago. de 2025, 22:40 UTC

Ganhos

Sandfire Resources Net Debt $123 Million at June 30

27 de ago. de 2025, 22:40 UTC

Ganhos

Sandfire Resources FY Underlying Ebitda $527.7 Million

Comparação entre Pares

Variação de preço

MannKind Corp Previsão

Preço-alvo

By TipRanks

108.63% parte superior

Previsão para 12 meses

Média 9.43 USD  108.63%

Máximo 12 USD

Mínimo 7 USD

Com base em 7 analistas de Wall Street que oferecem metas de preço de 12 meses para MannKind Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

7 ratings

7

Comprar

0

Manter

0

Vender

Pontuação Técnica

By Trading Central

4.079 / 4.323Suporte e Resistência

Curto Prazo

Bullish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Weak Bearish Evidence

Sentimento

By Acuity

351 / 372 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Baixa

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre MannKind Corp

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.